Gallant JE - Search Results

1

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: gallant je. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

2

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Lucas GM, Gallant JE, Moore RD. Lucas GM, et al. Among authors: gallant je. AIDS. 2004 Jul 23;18(11):1539-48. doi: 10.1097/01.aids.0000131339.68666.1a. AIDS. 2004. PMID: 15238772

3

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF. Nettles RE, et al. Among authors: gallant je. Clin Infect Dis. 2004 Oct 1;39(7):1030-7. doi: 10.1086/423388. Epub 2004 Sep 1. Clin Infect Dis. 2004. PMID: 15472857

4

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Gallant JE, Parish MA, Keruly JC, Moore RD. Gallant JE, et al. Clin Infect Dis. 2005 Apr 15;40(8):1194-8. doi: 10.1086/428840. Epub 2005 Mar 17. Clin Infect Dis. 2005. PMID: 15791522 Clinical Trial.

5

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF. Siliciano JD, et al. Among authors: gallant je. J Infect Dis. 2007 Mar 15;195(6):833-6. doi: 10.1086/511823. Epub 2007 Jan 30. J Infect Dis. 2007. PMID: 17299713

6

Renal function with use of a tenofovir-containing initial antiretroviral regimen.

Gallant JE, Moore RD. Gallant JE, et al. AIDS. 2009 Sep 24;23(15):1971-5. doi: 10.1097/QAD.0b013e32832c96e9. AIDS. 2009. PMID: 19696652 Free PMC article.

7

High-risk behavior and potential transmission of drug-resistant HIV among injection drug users.

Sethi AK, Celentano DD, Gange SJ, Gallant JE, Vlahov D, Farzadegan H. Sethi AK, et al. Among authors: gallant je. J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):503-10. doi: 10.1097/00126334-200404150-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15021315

8

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.

Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Gallant JE, et al. J Infect Dis. 1992 Dec;166(6):1223-7. doi: 10.1093/infdis/166.6.1223. J Infect Dis. 1992. PMID: 1358986

9

Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.

Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Gallant JE, et al. J Infect Dis. 1995 Aug;172(2):346-52. doi: 10.1093/infdis/172.2.346. J Infect Dis. 1995. PMID: 7622876 Clinical Trial.

10

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Maenza JR, et al. Among authors: gallant je. J Infect Dis. 1996 Jan;173(1):219-25. doi: 10.1093/infdis/173.1.219. J Infect Dis. 1996. PMID: 8537662

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters